Korro Bio reported Q3 results and outlined upcoming pipeline milestones. The update follows preclinical data showing KRRO-111 cut pathogenic Z-AAT in liver tiss

Korro Bio reported Q3 results and outlined upcoming pipeline milestones. The update follows preclinical data showing KRRO-111 cut pathogenic Z-AAT in liver tissue by up to 95%, with further OPERA RNA editing platform progress due at OTS2026.